NAUT vs. QSI, QTRX, MASS, FEIM, KEQU, RPID, OWLT, SEER, OPXS, and PRE
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Quantum-Si (QSI), Quanterix (QTRX), 908 Devices (MASS), Frequency Electronics (FEIM), Kewaunee Scientific (KEQU), Rapid Micro Biosystems (RPID), Owlet (OWLT), Seer (SEER), Optex Systems (OPXS), and Prenetics Global (PRE). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs. Its Competitors
Quantum-Si (NASDAQ:QSI) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.
39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 30.0% of Quantum-Si shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Nautilus Biotechnology has a net margin of 0.00% compared to Quantum-Si's net margin of -2,925.41%. Nautilus Biotechnology's return on equity of -31.87% beat Quantum-Si's return on equity.
In the previous week, Quantum-Si and Quantum-Si both had 2 articles in the media. Quantum-Si's average media sentiment score of 1.33 beat Nautilus Biotechnology's score of 1.06 indicating that Quantum-Si is being referred to more favorably in the media.
Quantum-Si has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Nautilus Biotechnology has lower revenue, but higher earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Quantum-Si presently has a consensus target price of $3.48, indicating a potential upside of 80.05%. Nautilus Biotechnology has a consensus target price of $2.13, indicating a potential upside of 180.38%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Quantum-Si.
Summary
Nautilus Biotechnology beats Quantum-Si on 9 of the 14 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 7/25/2025 by MarketBeat.com Staff
